Dosimetric comparison between single-channel and six-channel vaginal cylinders with three-dimensional treatment planning in postoperative brachytherapy for endometrial carcinoma
Hou Xiaorong*, Yum Land, Shan Shucan, Hu Ke, Shen Jie, Lian Xin, Sun Shuai, Yan Junfang, Liu Zhikai, Yang Bo, Qiu Jie, Zhang Fuquan, Li Yexiong
*Department of Radiation Oncology,Cancer Hospital,Pecking Union Medical College Hospital,Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
Abstract：Objective To evaluate whether the three-dimensional (3D) CT-guided treatment planning for postoperative brachytherapy of endometrial carcinoma offers any advantage over the two-dimensional (2D) planning with single-channel and six-channel vaginal cylinders. Methods Ten patients with endometrial carcinoma treated with vaginal brachytherapy were included. Patients had CT scan with six-channel and single-channel vaginal cylinders. The clinical target volume (CTV) was defined by the upper 3 cm of vagina and submucous 5 mm in all directions. The dose prescribed was 5 Gy with six fractions. Each patient with various cylinders underwent 2D and 3D planning. The doses of CTV and organ at risk (OAR) were compared between 2D and 3D treatment planning between two cylinders. Results Both 2D and 3D plans for two cylinders showed excellent dose coverage to the CTV. Compared with 2D plan, 3D plan with single-channel vaginal cylinder significantly decreased the doses of 0.1, 1.0, and 2.0 cm3 to the rectum by 18.2%, 12.4%, and 10.7%. Similarly, 3D plans with six-channel vaginal cylinder significantly decreased the doses of 0.1, 1.0, 2.0 cm3, and Dmean to the rectum by 36.6%, 24.8%, 20.4%, and 6.1%. In addition, it reduced the Dmean to the bladder and urethra. Compared with 3D plan for single-channel vaginal cylinder, 3D plan for six-channel vaginal cylinder significantly decreased the doses of the rectum, bladderand small intestine. Conclusions Three-dimensional CT-guided treatment planning, especially 3D plan for six-channel vaginal cylinder, for postoperative brachytherapy of endometrial carcinoma decreased the doses to critical organs without compromising coverage of CTV with various cylinders.
. Dosimetric comparison between single-channel and six-channel vaginal cylinders with three-dimensional treatment planning in postoperative brachytherapy for endometrial carcinoma[J]. Chinese Journal of Radiation Oncology, 2015, 24(1): 60-64.
[1] Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma:multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma[J]. Lancet,2000,355(9213):1404-1411. [2] Keys HM, Roberts JA, Brunetto VL, et al. A phase Ⅲ trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma:a gynecologic oncology group study[J]. Gynecol Oncol,2004,92(3):744-751. [3] ASTEC/EN.5 study group, Blake P, Swart AM,et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials):pooled trial results, systematic review, and meta-analysis[J]. Lancet,2009,373(9658):137-146.DOI:10.1016/S0140-6736(08)61767-5. [4] Aalders J, Abeler V, Kolstad P, et al. Postoperative external irradiation and prognostic parameters in stage Ⅰ endometrial carcinoma:clinical and histopathologic study of 540 patients[J]. Obstet Gynecol,1980,56(4):419-427. [5] Patel MK, Cote ML, Ali-Fehmi R, et al. Trends in the utilization of adjuvant vaginal cuff brachytherapy and/or external beam radiation treatment in stage Ⅰ and Ⅱ endometrial cancer:a surveillance, epidemiology, and end-results study[J]. Int J Radiat Oncol Biol Phys,2012,83(1):178-184.DOI:10.1016/j.ijrobp.2011.05.052. [6] Nout RA, Putter H, Jurgenliemk-Schulz IM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer:first results of the randomized PORTEC-2 trial[J]. J Clin Oncol,2009,27(21):3547-3556.DOI:10.1200/JCO.2008.20.2424. [7] Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2):an open-label, non-inferiority, randomised trial[J]. Lancet,2010,375(9717):816-823.DOI:10.1016/S0140-6736(09)62163-2. [8] Ko EM, Funk MJ, Clark LH, et al. Did GOG99 and PORTEC1 change clinical practice in the United States?[J]. Gynecol Oncol,2013,129(1):12-17.DOI:10.1016/j.ygyno.2013.01.020. [9] Patel MK, Cote ML, Ali-Fehmi R, et al. Trends in the utilization of adjuvant vaginal cuff brachytherapy and/or external beam radiation treatment in stage Ⅰ and Ⅱ endometrial cancer:a surveillance, epidemiology, and end-results study[J]. Int J Radiat Oncol Biol Phys,2012,83(1):178-184.DOI:10.1016/j.ijrobp.2011.05.052. [10] Alektiar KM, Venkatraman E, Chi DS, et al. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer[J]. Int J Radiat Oncol Biol Phys,2005,62(1):111-117. [11] Atahan IL, Ozyar E, Yildiz F, et al. Vaginal high dose rate brachytherapy alone in patients with intermediate-to high-risk stage Ⅰ endometrial carcinoma after radical surgery[J]. Int J Gynecol Cancer,2008,18(6):1294-1299.DOI:10.1111/j.1525-1438.2008.01198.x. [12] Jolly S, Vargas C, Kumar T, et al. Vaginal brachytherapy alone:an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer[J]. Gynecol Oncol,2005,97(3):887-892. [13] Lin LL, Mutch DG, Rader JS, et al. External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer[J]. Gynecol Oncol,2007,106(1):215-220. [14] Solhjem MC, Petersen IA, Haddock MG. Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage Ⅰ endometrial cancer[J]. Int J Radiat Oncol Biol Phys,2005,62(5):1379-1384. [15] Kim H, Kim H, Houser C, et al. Is there any advantage to three-dimensional planning for vaginal cuff brachytherapy?[J]. Brachytherapy,2012,11(5):398-401.DOI:10.1016/j.brachy.2011.12.009. [16] Kim H, Rajagopalan MS, Houser C, et al. Dosimetric comparison of multichannel with one single-channel vaginal cylinder for vaginal cancer treatments with high-dose-rate brachytherapy[J]. Brachytherapy,2014,13(3):263-267.DOI:10.1016/j.brachy.2013.08.009. [17] Small W Jr, Beriwal S, Demanes DJ, et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy[J]. Brachytherapy,2012,11(1):58-67.DOI:10.1016/j.brachy. 2011.08.005. [18] El Khoury C, Dumas I, Tailleur A, et al. Adjuvant brachytherapy for endometrial cancer:advantages of the vaginal mold technique[J]. Brachytherapy,2014,4721 Supll 1538(14):589-593.DOI:10.1016/j. brachy. 2014.07.007. [19] Richardson S, Palaniswaamy G, Grigsby P. Dosimetric effects of air pockets around high-dose rate brachytherapy vaginal cylinders[J]. Int J Radiat Oncol Biol Phys,2010,78(1):276-279.DOI:10.1016/j.ijrobp.2009.11.004. [20] Cameron AL, Cornes P, Al-Booz H. Brachytherapy in endometrial cancer:Quantification of air gaps around a vaginal cylinder[J]. Brachytherapy,2008,7(4):355-358.DOI:10.1016/j.brachy.2008.07.004.
2015, Vol. 24 
